Abstract
CYP2C9 is a polymorphic enzyme that metabolizes a number of clinically important drugs. In this study, catalytic activities of seven alleles found in Japanese individuals, CYP2C9*3 (I359L), *13 (L90P), *26 (T130R), *28 (Q214L), *30 (A477T), *33 (R132Q), and *34 (R335Q), were assessed using three substrates (diclofenac, losartan, and glimepiride). When expressed in a baculovirus-insect cell system, the holo and total (apo and holo) CYP2C9 protein expression levels were similar among the wild type (CYP2C9.1) and six variants except for CYP2C9.13. A large part of CYP2C9.13 was present in the apo form P420. Compared with CYP2C9.1, all variants except for CYP2C9.34 exhibited substrate-dependent changes in Km, Vmax, and intrinsic clearance (Vmax/Km). For diclofenac 4′-hydroxylation, the intrinsic clearance was decreased markedly (by >80%) in CYP2C9.13, CYP2C9.30, and CYP2C9.33 and variably (63–76%) in CYP2C9.3, CYP2C9.26, and CYP2C9.28 due to increased Km and/or decreased Vmax values. For losartan oxidation, CYP2C9.13 and CYP2C9.28 showed 2.5- and 1.8-fold higher Km values, respectively, and all variants except for CYP2C9.34 showed >77% lower Vmax and intrinsic clearance values. For glimepiride hydroxylation, the Km of CYP2C9.13 was increased 7-fold, and the Vmax values of all variants significantly decreased, resulting in reductions in the intrinsic clearance by >80% in CYP2C9.3, CYP2C9.13, CYP2C9.26, and CYP2C9.33 and by 56 to 75% in CYP2C9.28 and CYP2C9.30. These findings suggest the necessity for careful administration of losartan and glimepiride to patients bearing these six alleles.
Footnotes
-
This study was supported in part by the Program for the Promotion of Fundamental Studies in Health Sciences from the National Institute of Biomedical Innovation; and by the Health and Labor Sciences Research Grants from the Ministry of Health, Labor and Welfare.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.109.027003.
-
ABBREVIATIONS: P450, cytochrome P450; OR, NADPH P450 reductase; ANOVA, analysis of variance; SRS, substrate recognition site.
- Accepted June 15, 2009.
- Received February 4, 2009.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|